简介 联系方式 相互作用: 118 620
根据名称进行药物检索

Diazepam Oral Concentrate与肾/肝病

Diazepam Oral Concentrate与肾/肝病安全配伍检测的结果。

检测结果:
Diazepam Oral Concentrate <> 肾/肝病
现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

苯并二氮杂卓的代谢通过的肝脏，和代谢物的排出的尿液。 氯氮卓、氯硝西ate、地西泮、氟西泮和瓜西p经过氧化N-脱以活动的代谢产物是基本上不再起作用于母体化合物。 这些代谢物然后接受进一步的生物转化到药理学上不活跃产品之前，排泄物通过的肾脏。 治疗与苯并二氮杂卓应给予谨慎地在较低的初步剂量的患者的肾受损以及/或肝功能。 代理转换为弱的活动，短效，或者不活跃的代谢物可能优于肝功能损害。 劳拉西泮、奥沙西泮和替马西泮是偶为不活跃的代谢产物，而阿普唑仑、艾司唑仑和三唑仑经历羟基化为弱活跃或不活跃的代谢物。

来源
  • Dehlin O, Kullingsjo H, Liden A, Agrell B, Moser G, Olsen I "Pharmacokinetics of alprazolam in geriatric patients with neurotic depression." Pharmacol Toxicol 68 (1991): 121-4
  • Murray TG, Chiang ST, Koepke HH, Walker BR "Renal disease, age, and oxazepam kinetics." Clin Pharmacol Ther 30 (1981): 805-9
  • de Silva JAF, Strojny N "Determination of flurazepam and its major biotransformation products in blood and urine by spectrophotofluorometry and spectrophotometry." J Pharm Sci 60 (1971): 1303-14
  • "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • Ghabrial H, Desmond PV, Watson KJ, et al "The effects of age and chronic liver disease on the elimination of temazepam." Eur J Clin Pharmacol 30 (1986): 93-7
  • "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  • "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • Chung M, Hilbert JM, Gural RP, Radwanski E, Symchowicz S, Zampaglione N "Multiple-dose quazepam kinetics." Clin Pharmacol Ther 35 (1984): 520-4
  • Allen MD, Greenblatt DJ, Arnold JD "Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine." Psychopharmacology (Berl) 66 (1979): 267-74
  • Klotz U, Avant GR, Hoyumpa A, Schenker S, Wikinson GR "The effects of age and liver disease on the disposition and elimination of diazepam in adult man." J Clin Invest 55 (1975): 347-59
  • Wilensky AJ, Levy RH, Troupin AS, Moretti-Ojemann L "Clorazepate kinetics in treated epileptics." Clin Pharmacol Ther 24 (1978): 22-30
  • Greenblatt DJ, Divoll MK, Soong MH, Boxenbaum HG, Harmatz JS, Shader RI "Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam." J Clin Pharmacol 28 (1988): 853-9
  • Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985): 839-42
  • Schmith VD, Piraino B, Smith RB, Kroboth PD "Alprazolam in end-stage renal disease: I. Pharmacokinetics." J Clin Pharmacol 31 (1991): 571-9
  • "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  • Kroboth PD, Smith RB, Van Thiel DH, Juhl RP "Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects." J Clin Pharmacol 27 (1987): 555-60
  • Hilbert JM, Chung M, Radwanski E, Gural R, Symchowicz S, Zampaglione N "Quazepam kinetics in the elderly." Clin Pharmacol Ther 36 (1984): 566-9
  • "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985): 453-9
  • "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  • Juhl RP, Van Thiel DH, Dittert LW, Smith RB "Alprazolam pharmacokinetics in alcoholic liver disease." J Clin Pharmacol 24 (1984): 113-9
  • Tedesco FJ, Mills LR "Diazepam (valium) hepatitis." Dig Dis Sci 27 (1982): 470-2
  • Cutler RE, Blair AD "Pharmacokinetics of diazepam in normal and uremic humans." Clin Pharmacol Ther 25 (1979): 219-20
  • Hoyumpa AM "Disposition and elimination of minor tranquilizers in the aged and in patients with liver disease." South Med J 71 (1978): 23-8
  • Johnson J, Padilla BG, Carter J, Holt JH, Ozawa T "Adverse effects of flurazepam in a hemodialysis patient." J Am Assoc Nephrol Nurses Tech 4 (1977): 93-5
  • "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  • Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ "Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam." Nephron 37 (1984): 100-4
  • "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  • "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  • American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  • Roberts RK, Wilkinson GR, Branch RA, Schenker S "Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium)." Gastroenterology 75 (1978): 479-85
  • "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  • Gustavson LE, Carrigan PJ "The clinical pharmacokinetics of single doses of estazolam." Am J Med 88 (1990): s2-5
  • Verbeeck RK, Tjandramaga TB, de Schepper PJ, Verberckmoes R "Impaired elimination of lorazepam following subchronic administration in two patients with renal failure." Br J Clin Pharmacol 12 (1981): 749-50
  • Morgan DD, Robinson JD, Mendenhall CL "Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis." Eur J Clin Pharmacol 19 (1981): 279-85
  • Greenblatt DJ, Divoll M, Harmatz JJ "Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs." Clin Pharmacol Ther 30 (1981): 475-86
  • "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Kaplan SA, de Silva JAF, Jack ML, et al "Blood level profile in man following chronic oral administration of flurazepam hydrochloride." J Pharm Sci 62 (1973): 1932-5
  • Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR "Effects of age and liver disease on disposition of lorazepam." Clin Pharmacol Ther 24 (1978): 411-9
  • Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernathy DR "Diazepam kinetics in patients with renal insufficiency or hyperthyroidism." Br J Clin Pharmacol 12 (1981): 829-32
  • "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  • Sellers EM, Greenblatt DJ, Giles HG, et al "Chlordiazepoxide and oxazepam disposition in cirrhosis." Clin Pharmacol Ther 26 (1979): 240-6
  • Greenblatt DJ "Clinical pharmacokinetics of oxazepam and lorazepam." Clin Pharmacokinet 6 (1981): 89-105
  • Sellers EM, Greenblatt DJ, Giles HG, et al "Chlordiazepoxide and oxazepam disposition in cirrhosis." Clin Pharmacol Ther 26 (1979): 240-6
  • Morrison G, Chiang ST, Koepke HH, Walker BR "Effect of renal impairment and hemodialysis on lorazepam kinetics." Clin Pharmacol Ther 35 (1984): 646-52
  • Hicks R, Dysken MW, Davis JM, et al "The pharmacokinetics of psychotropic medication in the elderly: a review." J Clin Psychiatry 42 (1981): 374-85
  • Busch U, Molzahn M, Bozler G, Koss FW "Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease." Arzneimittelforschung 31 (1981): 1507-11
Diazepam Oral Concentrate

非专利名称: diazepam

品牌: Valium, Diastat, Diastat AcuDial, Diastat Pediatric, Diazepam Intensol, Zetran

同义词: Diazepam

Diazepam Oral Concentrate是什么？
其他的药物 删除
Diazepam Oral Concentrate <> 肾/肝病
现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

使用地西泮被认为是可由制造商为被禁忌的患者的临床或生物化学证据的显着的肝脏疾病。 西泮是主要代谢通过的肝脏，和代谢产物是消除肾脏。 由于可能的过度积累的代谢物以及未知的影响的这种积累、治疗与安定，也应给予谨慎的患者的肾损伤。 监测肾功能在处理建议。

Diazepam Oral Concentrate

非专利名称: diazepam

品牌: Valium, Diastat, Diastat AcuDial, Diastat Pediatric, Diazepam Intensol, Zetran

同义词: Diazepam

Diazepam Oral Concentrate是什么？
其他的药物 删除
公认药物相互作用的清单
DiseDoc 和平
与食物，生活方式相互作用
  1. Diazepam Oral Concentrate
药物互相作用
  1. Diazepam Oral Concentrate
我们使用Cookie来优化网站性能。通过继续浏览这个网站,你同意使用Cookie。 同意